NCT06699329View on ClinicalTrials.gov

A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 22, 2024

Primary Completion Date

May 24, 2024

Study Completion Date

May 24, 2024

Conditions
Healthy
Interventions
DRUG

Enlicitide Decanoate

multiple doses, oral tablet

DRUG

Semaglutide

multiple doses, oral tablet

Trial Locations (1)

68502

Celerion (Site 0001), Lincoln

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06699329 - A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023) | Biotech Hunter | Biotech Hunter